Grifols‘ (MCE:GRF) $4 billion acquisition of Talecris Biotherapeutics (NASDAQ:TLCR) now has the regulatory clearance to close. Barcelona, Spain-based Grifols said Wednesday that the U.S. Federal Trade Commission has accepted a consent agreement that outlines the conditions for merger of the blood therapeutics companies. Last month, the FTC and the companies reached a preliminary agreement that […]
Talecris Biotherapeutics’ (NASDAQ:TLCR) $4 billion acquisition by Spanish company Grifols (MCE:GRF) looks like it will finally win regulatory approval. Barcelona-based Grifols said Monday that it has reached a preliminary agreement with the U.S. Federal Trade Commission that grants approval of the deal, but also calls for both blood therapeutics companies to sell certain assets. The […]
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
The Talecris Biotherapeutics acquisition by Spanish company Grifols (MCE:GRF) looks like it’s moving closer to receiving regulatory approval, at least that’s how stock traders view the deal. Bloomberg Businessweek reports that investors have grown more bullish on Talecris (NASDAQ:TLCR), particularly since the Research Triangle Park, North Carolina company extended the deadline to close the $3.4 […]